Expression of PlGF splice variants was not correlated with clinical variables. Interestingly, expression levels of VEGFR-1 predict presence of DTCs in bone marrow (p = 0.002). Patients with DTC in ...

PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. Clinical Cancer Research, 2016; DOI: 10.1158/1078-0432.CCR-15-1839 ...

In order to wisely skirt this catastrophic event, Lois E. H. Smith and colleagues utilized placental growth factor-1 (PlGF-1), which exclusively activates the VEGF receptor-1 (VEGFR-1).

Similar to PlGF, its receptor, vascular endothelial growth factor receptor 1 (VEGFR-1, formerly termed Flt-1), was expressed at high levels in rheumatoid synovium and in PBMCs from patients with ...

They also found that targeting the PlGF/VEGFR-1 interaction prevents weight gain in a genetically obese mouse model but worsens a diabetes-like condition, a worsening that was alleviated by use of ...

1. Incio J, Tam J, Rahbari NN, et al. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity [published online February 9, 2016].

Their findings in cellular and animal models, as well as in patient tumor samples, indicate that targeting the PlGF/ VEGFR-1 pathway may be particularly effective in obese patients.

PLGF binds only to VEGFR-1, which is also present on the surface of leucocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability.

We first confirmed that the serum levels of sFlt-1, free PlGF, and free VEGF were altered in women with clinical preeclampsia. 5,8 Among 23 pairs of women with preeclampsia and controls with ...

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the ...

More information: J. Incio et al. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity, Clinical Cancer Research (2016).